Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
10,416 results in Europe PMC
PubMed plus preprints and full-text open access papers. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Impact of resolved hepatitis B virus infection on clinical outcomes in patients with diffuse large B-cell lymphoma: a supplementary analysis of JCOG0601.
Hagiwara S, Kusumoto S, Machida R, Ohmachi K, Makiyama J, Munakata W, Ando K, Kinoshita T, Tsukasaki K, Nagai H, Maruyama D. · Int J Hematol · 2026 · cited 0 timesclinical trial, phase iii, clinical trial, phase ii
- Efficacy and safety of ifupinostat in relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase 2 study.
Shi Y, Liu P, Li Y, Li W, Zhou H, Yang Y, Jin J, Gao Y, Xu W, Zheng M, Yang H, Xue H, Peng Z, Bai O, Li F, Lv F, Zhang L, Huang N, Luo Y, Hu C, Xu Y, Zhang H, Sun X, Li X, Ding K, Zeng L, Zhu H, Cao Y, Yang Y, Jiang K, Qian C. · Signal Transduct Target Ther · 2026 · cited 0 timesOpen accessclinical trial, phase ii, multicenter study
- Febrile neutropenia in adults with diffuse large B-cell lymphoma receiving first-line R-CHOP-based therapy: a systematic review and meta-analysis of observational and trial evidence.
Reyes J, Reyes A. · Support Care Cancer · 2026 · cited 0 timesmeta-analysis, systematic review
- Efficacy of zanubrutinib in diffuse large B-cell lymphoma: A single-arm meta-analysis.
Sun P, Yang H, Li B, Wang Y, Liu P, Li Z. · Crit Rev Oncol Hematol · 2026 · cited 0 timesmeta-analysis, systematic review
- Outcomes of loncastuximab tesirine in heavily pretreated patients with diffuse large B-cell lymphoma, including the post-CAR T-cell therapy setting: A meta-analysis.
Gibran-Nunes F, Pêcego H, Santos J, Nunes Y, Freitas B, Rena J, Fogale M, Ferreira A, Seiwald M, Xue E, Cortez A, Fonseca A, Xavier E, Serpa M, Tucunduva L, Novis Y. · Cancer · 2026 · cited 1 timesmeta-analysis, systematic review
- Efficacy and safety of loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a systematic review and meta-analysis.
Khan A, Habib H, Butt AI, Khan I, Aziz K, Alokozay E, Kamran H, Qasim SA, Saleem A, Ijaz S, Khan B, Karimi MS, Malik SJ, Elahi A, Sandoval-Sus J. · Syst Rev · 2026 · cited 1 timesOpen accessmeta-analysis, systematic review
- The Prognostic Role of Interim [18F]FDG PET/CT in Diffuse Large B-Cell Lymphoma: An Updated Systematic Review and Meta-analysis.
Albano D, Chauvie S, Rizzo A, Bertagna F, Casadei B, Vitolo U, Tucci A, Zinzani PL, Guerra L. · Clin Lymphoma Myeloma Leuk · 2026 · cited 1 timesmeta-analysis, systematic review
- A Phase I Study of Copanlisib and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Crombie JL, Kim AI, Redd R, Bartlett N, Patterson V, Carey C, Balasubramanian S, Odejide O, Merryman RW, LaCasce A, Jacobson CA, Jacobsen E, Parry E, Fisher D, Herrera A, Davids MS, Shipp M, Armand P, Shouse G. · Clin Lymphoma Myeloma Leuk · 2026 · cited 1 timesmulticenter study, clinical trial, phase i
- Mecapegfilgrastim for Prophylaxis of Immunochemotherapy-Induced Neutropenia in Patients With Diffuse Large B-Cell Lymphoma: A Multicenter Pilot Trial.
Wang J, Li H, Lin Q, Guo Y, Ma H, Xiang B, Yang C, Shen K, Zhang C, Yang K, Ma C, Zhai H, Wei J, Zuo Y, Zhou J, Niu T. · Cancer Med · 2026 · cited 0 timesOpen accessmulticenter study, randomized controlled trial
- Evaluating the prognostic value of body mass index in diffuse large B-cell lymphoma: a systematic review and meta-analysis.
Su L, Tian Y, Li Y, Zhang Y, Chang A, Yuan G, Jiao Y, Wu J. · Front Nutr · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
- ZR2-miniCHOP for elderly patients with newly diagnosed diffuse large B-cell lymphoma.
Sun J, Xu Y, Zheng X, Wang H, Yu W, Zhou X, Zhou, Yang C, Wang Z, Yu F, Zhao Y, Yan J, Meng H, Goli MM, Ghanad P, Tong H, Jin J, Xie W. · BMC Cancer · 2026 · cited 0 timesOpen accessclinical trial, phase ii
- Phase I study of oral azacitidine plus salvage chemotherapy in relapsed/refractory diffuse large B-cell lymphoma.
Hess B, Wagner-Johnston ND, Hendrickson L, Davis JA, Hill E, Giri A, Armeson K, Revuelta MV, Salzer S, Klingenberg R, Cerchietti L. · Ann Hematol · 2026 · cited 0 timesOpen accessclinical trial, phase i
- Comparative efficacy and toxicity of Axicabtagene Ciloleucel <i>versus</i> Tisagenlecleucel in European patients with large B-cell lymphoma: a systematic review and meta-analysis.
Li H, Liu Y, Wang T, Zhong K, Xiao J, Huang X. · PeerJ · 2026 · cited 0 timesOpen accessmeta-analysis, comparative study
- Phase 1 study of zanubrutinib plus lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.
Song Z, Cheng Y, Yang H, Zhang L, Zou L, Guo Y, Cao J, Huang H, Wang Z, Huang S, Fang Y, Lyu J, Zhang Y, Liu Y, Zhou K, Zhang H. · Blood Adv · 2026 · cited 2 timesOpen accessmulticenter study, clinical trial, phase i
- Maintenance treatment and survival in patients with newly diagnosed diffuse large B cell lymphoma in the immunochemotherapy era: a systematic review and network meta-analysis.
Wang J, Zhou D, Lv C, Zhou M, Xu J, Zhou R, Wan Y. · Clin Transl Oncol · 2026 · cited 0 timessystematic review, network meta-analysis
- Ultralow-Dose Interleukin 10-Expressing Chimeric Antigen Receptor T Cells in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Nonrandomized Clinical Trial.
Hu Y, Zhang M, Gao M, Dong Y, Fu S, Li Y, Zhu X, Feng J, Hong R, Wei G, Zhao D, Cui J, Huang S, Yang T, Bai D, Cheng B, Cui Y, Ren J, Liu C, Li Y, Chen Q, Zhou Z, Wang D, Guo Y, Tang L, Wang X, Huang H. · JAMA Oncol · 2026 · cited 1 timesclinical trial, phase i
- Efficacy of bispecific T-cell engagers after CAR T-cell therapy failure in aggressive large B-cell lymphoma.
Kharfan-Dabaja MA, Reljic T, Abdel-Razeq S, Sarhan Z, Mohty R, Keller K, Iqbal M, Chavez JC, Luo Y, Qin H, Aljurf M, Kumar A. · Curr Res Transl Med · 2026 · cited 0 timesmeta-analysis, systematic review
- Pola-R-CHP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of randomized trials and real-world evidence.
Perrone S, Molica M, Giannarelli D, Pacitto G, Ferrero S. · Blood Cancer J · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Risks and benefits for patients with relapsed or refractory diffuse large B-cell lymphoma in early-phase clinical trials: a systematic review and meta-analysis.
Spanjaart AM, Bakker M, de Vries R, Hutten BA, van Nieuwenhuijzen N, Minnema MC, Kuipers MT, Kersten MJ. · Lancet Haematol · 2026 · cited 1 timesmeta-analysis, systematic review
- The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B-Cell Lymphoma (CLSG-CNS-01): A Randomized, Multicenter, Prospective Phase 3 Trial.
Mocikova H, Gaherova L, Jancarkova T, Suri A, Janikova A, Steinerova K, Belada D, Pytlik R, Duras J, Trnkova M, Blahovcova P, Kozak T, Trneny M. · Hematol Oncol · 2026 · cited 1 timesOpen accessclinical trial, phase iii, multicenter study
- Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study.
Zhang Q, Jiang S, Wei R, Zhang W, Bao L, Liu Y, Jin J, Lv F, Liu C, Liu X, Sun H, Wang J, Tao R, Zhou X, Cao J. · Blood Cancer J · 2026 · cited 1 timesOpen accessclinical trial, phase ii
- Baseline Tumor Transcriptional Features and Event-Free Survival After Anti-CD19 CAR T-Cell Therapy with Axicabtagene Ciloleucel in Large B-Cell Lymphoma: An Exploratory Reanalysis of the Randomized ZUMA-7 Trial.
Souza Resende JS, Giner IS, Custodio de Figueiredo MG, Paraízo MM, Lalli E, Castro MAA, Figueiredo BC. · Med Sci (Basel) · 2026 · cited 0 timesOpen accessrandomized controlled trial
- R-MINE-containing regimen in relapsed and refractory diffuse large B-cell lymphoma: a single-arm, multicenter phase II study.
Liang JH, Zhang XY, Bi LT, Qin WW, Su LP, Liu JB, Wu JZ, Yin H, Kong YL, Shen HR, Li JY, Li Y, Wang L, Xu W. · BMC Med · 2026 · cited 0 timesOpen accessclinical trial, phase ii, research support, non-u.s. gov't
- Network meta-analysis of first-line R-CHOP-based regimens in MYC/BCL2 double-expressor diffuse large B-cell lymphoma.
Cheng H, Zeng L, Li X, Ke Q, Sun J, Guo B, Tan X, Cen H, Liao C. · Front Immunol · 2026 · cited 0 timesOpen accessnetwork meta-analysis
- Risk stratification of patients with diffuse large B-cell lymphoma using plasma NMR-based metabolomics at diagnosis.
Montagne A, Bertho G, Papastergiou T, Chartier L, Ricci R, Jardin F, Ghesquières H, Rossi C, Morschhauser F, Haioun C, Ribrag V, Feugier P, Brisou G, Oberic L, Gaulard P, Giraud N, Bennani Y, Thieblemont C, Baud V. · Blood Adv · 2026 · cited 0 timesOpen accessclinical trial, phase iii, multicenter study
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.